-
We Are A Specialty Care
Biopharma CompanyCommitted To Bringing Transformational Therapies
To Patients In China And Asia -
Fit For Purpose
We Transcend Clinical Application Insights That Drive Our
Clinical Development Strategy Through A Dual Wheel Model
Of Our Integrated Commercial Platform And Late Stage
Clinical Pipeline -
Specialty Care
BoutiqueWe Focus On Developing First-in-Class Innovative Pipeline
To Address Unmet Medical Needs In Respiratory For The
Vast Patient Community In Asia -
Asia Pac Vision
We Are Passionate About Exploring APAC Business Opportunities
And Have Substantive Progress In Our Asian Expansion Strategy
Bringing Therapies That Are More Accessible To People In China And Asia
Our Area Of Focus
We Have Developed A Differentiated Matrix Of Commercial Products And Innovative Pipeline Across Respiratory, Emergency Care, Iron Deficiency Anemia, Pain Management
Highlights
Founded by Mark Lotter in 2014, Nuance deploys the Dual Wheel model that develops a leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia
-
5PRODUCTS
COMMERCIAL
-
4PIPELINE
LATE STAGE CLINICAL
-
300+
EMPLOYEES WORLDWIDE
Our Transformative Journey
-
-
-
2022
Launched nasal spray Bentrio™ in Hong Kong
Licensed in allergy alleviation / virus prevention nasal spray Bentrio™ from Altamira Therapeutics
-
2021
Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma
Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma
Acquired Sino Health with access to 3 emergency care products and a GSP license in Zhuhai
-
2020
Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum
Raised US$ 181 million Series D equity funding
-
-
2018
Established partnership with Aerogen Pharma on nebulizer device
Accumulatively raised US$ 80 million equity funding
-
2024
2023
2022
2021
2020
2019
2018
2014
-
2024
-
2023
-
2022
-
2021
-
2020
-
2019
-
2018
-
2014
News
-
2024-09-11
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
Nuance Pharma announced it has completed the recruitment of patients for the ENHANCE-CHINA study, after planned number of patients have been successfully enrolled.
-
2024-08-14
PharmaBoardroom Interview with Nuance Pharma founder & CEO Mark Lotter
From a demographic and disease profile perspective, Asia-Pacific shares more similarities with China than with Western markets. This alignment makes expanding into Asia-Pacific a logical step.
-
2022-11-28
Partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau
Nuance Pharma announces partnership with DKSH Hong Kong (DKSH HK) Business Unit Healthcare to launch BentrioTM nasal spray in Hong Kong and Macau, marking the very first milestone of Nuance
CONTACT
Suite 639, East Tower, No 1376 Nan Jing West Road, Shanghai. 200040
Copyright 2023 NUANCE BIOTECH reserved. 沪ICP备17029781号-4